Biomarkers of the osteoprotegerin pathway: Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 9, 2010, Pages 1849-1854

  Lieb, Wolfgang ^a   Gona, Philimon ^a,b   Larson, Martin G ^a,b   Massaro, Joseph M ^a,b   Lipinska, Izabella ^c   Keaney, John F ^d   Rong, Jian ^a   Corey, Diane ^a   Hoffmann, Udo ^g   Fox, Caroline S ^a,e   Vasan, Ramachandran S ^a,c   Benjamin, Emelia J ^a,b,c   Odonnell, Christopher J ^a,f,i   Kathiresan, Sekar ^f,h  

^a FRAMINGHAM HEART STUDY   (United States)

^b School of Public Health   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Center for Human Genetic Research ^*  (United States)

^g Center for Human Genetic Research   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

coronary heart disease; osteoprotegerin; receptor activator of nuclear factor B ligand; vascular biology

Indexed keywords

BIOLOGICAL MARKER; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGE; ARTERY CALCIFICATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY; DIABETES MELLITUS; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CALCINOSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; MIDDLE AGED; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME;

AGED; BIOLOGICAL MARKERS; CALCINOSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANK LIGAND; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955983144     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.199661     Document Type: Article

References (27)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
2. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89:309-319.
3. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801-811.
4. Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS, Rho J, Mochizuki N, Kim YM, Oh GT, Kwon YG. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood. 2007;109: 1495-1502.
5. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95: 1046-1057.
6. Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B. Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857-863.
7. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275: 20959-20962.
8. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
9. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-1616.
10. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, Raffa S, D'anneo G, Luca F, Mioni C, Arrigo F, Squadrito F. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005;109:389-395.
11. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194.
12. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-633.
13. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-11280
14. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, Santer P, Mayr A, Xu Q, Willeit J. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116:385-391.
15. Browner WS, Lui LY, Cummings SR. Associations of serum osteopro-tegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-637.
16. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol. 2009;29: 975-980.
17. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring study. Am J Epidemiol. 1979;110:281-290.
18. Parikh NI, Hwang SJ, Larson MG, Cupples LA, Fox CS, Manders ES, Murabito JM, Massaro JM, Hoffmann U, O'Donnell CJ. Parental occurrence of premature cardiovascular disease predicts increased coronary artery and abdominal aortic calcification in the Framingham Offspring and Third Generation cohorts. Circulation. 2007;116: 1473-1481.
19. Kannel WB, Wolf PA, Garrison RJ. Section 34: some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. The Framingham Heart Study, 30-year follow-up: an epidemiological investigation. Bethesda, Md: National Heart, Lung and Blood Institute; 1987;1-26.
20. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation. 2003;107:e76.
21. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, De Lemos JA. Relation of osteopro-tegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518.
22. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. Soluble RANKL and risk of nontraumatic fracture. J Am Med Assoc. 2004;291:1108-1113.
23. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
24. Smith MR, Egerdie B, Hernandez TN, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
25. Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, Matsuhisa M, Ito T, Imai E, Hori M. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Re. 2008;31:1163-1170.
26. Van Campenhout A, Clancy P, Golledge J. Serum osteoprotegerin as a biomarker for vascular disease. Am J Cardiol. 2007;100:561.
27. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W, Kabaya T, Nihei H. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19: 1886-1889.